title: [Therapy of chronic myeloid leukemia with interferon-alpha. A decade of experiences].
abstract: RESULTS
  One hundred and fifty-nine patients with chronic myelogenous leukemia have been treated in six studies during 10 years at Hannover Medical School University Center. The prognosis of 111 patients without pretreatment has been improved compared to conventional therapy with a median survival of 5.7 years. Cytogenetic remissions have been induced in all studies followed for a longer time. The most pronounced improvement of prognosis has been observed in these patients.
  
  
  CONCLUSIONS
  Several conclusions can be drawn on the basis of the results on the different treatment concepts: 1. Patients with pretreatment have an unfavourable response to interferon. 2. There is a likely effect of the dose of Interferon alpha on the frequency of cytogenetic remissions. 3. The combination of Interferon alpha and interferon gamma has been toxic and ineffective in a pilot study. 4. The combination of interferon and cytosine arabinoside has a positive impact on the frequency of cytogenetic remissions. A continuous parallel application of both drugs seems to be most effective in this respect. An ongoing trial has been initiated to compare a fixed combination of Interferon alpha and cytosine arabinoside and with hydroxyurea respectively. Additionally the feasibility of autologous peripheral blood stem cell transplantation will be studied in patients with insufficient response to the interferon treatment.
authors.affiliation: Abteilung für Hämatologie und Onkologie, Medizinische Hochschule Hannover.
authors.forename: M
authors.initials: M
authors.lastname: Freund
authors.forename: P
authors.initials: P
authors.lastname: Heussner
authors.forename: F
authors.initials: F
authors.lastname: Hild
authors.forename: R
authors.initials: R
authors.lastname: Nowak
authors.forename: A
authors.initials: A
authors.lastname: Grote-Metke
authors.forename: H
authors.initials: H
authors.lastname: Diedrich
authors.forename: O
authors.initials: O
authors.lastname: Koch
authors.forename: B
authors.initials: B
authors.lastname: Otremba
authors.forename: P
authors.initials: P
authors.lastname: von Wussow
authors.forename: H D
authors.initials: HD
authors.lastname: Kleine
authors.forename: J
authors.initials: J
authors.lastname: Meran
authors.forename: H
authors.initials: H
authors.lastname: Link
authors.forename: H F
authors.initials: HF
authors.lastname: Hinrichs
authors.forename: L
authors.initials: L
authors.lastname: Balleisen
authors.forename: C
authors.initials: C
authors.lastname: Fonatsch
authors.forename: H
authors.initials: H
authors.lastname: Poliwoda
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D007371:Interferon-gamma / Q000008:administration & dosage / Q000009:adverse effects; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D008134:Long-Term Care; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D003561:Cytarabine; D007371:Interferon-gamma
vernacular_title: Therapie der chronischen myeloischen Leukämie mit Interferon alpha. Erfahrungen aus einem Jahrzehnt.